heart infusion broth (Difco), pH 8-0, in two-fold dilutions from 0 3 lrg./ml. to 40 itg./ml. The tubes were incubated at 37°C., read after 18 hours, shaken, and read again after 24 hours. The lowest concentration of gentamicin which gave inhibition of bacterial growth was determined as the M.I.C. The M.B.C. was determined by subcultivation from the tubes showing no bacterial growth to blood agar plates and reading the lowest concentration of gentamicin from which no bacteria could grow after incubation overnight.
The M.I.C. and M.B.C. values for kanamycin and colistin were determined in the same manner.
The gentamicin activity at varying pH was investigated by determining the M.I.C. and M.B.C. at pH 5-0, 6-0, 7 0, and 8-0.
SERUM AND URINE CONCENTRATION Gentamicin' for parenteral use was supplied in a concentration of 30 mg./ml., and was injected intramuscularly twice daily at 12-hour intervals for seven days. Blood samples were taken on the first day one hour after the second dose. During the third day of treatment blood and urine samples were taken at one, four, eight, and 12 hours after the first dose and all urine was collected between the times of sampling. During the fifth day a total 24-hour urine sample was collected. Two blood samples were taken two and seven days after the treatment was concluded. The serum and urine were stored at minus 20°C. until the antibiotic concentration was determined using an agar-diffusion assay (Oden, Stander, and Weinstein, 1963) Table 1II ) with bacteriuria (more than 105 bacteria per ml. urine). The number of bacteria was determined by quantitative cultivation technique. In vitro sensitivity against gentamicin and other antibiotics was investigated before treatment. Before gentamicin therapy most of the patients had been treated with a number of antibiotics without prolonged freedom from bacteriuria. The dose of gentamicin administered was based upon bodyweight and kidney function measured as the endogenous creatinine clearance. Befone treatment, the patient's urine was made alkaline; the pH was tested daily during treatment and remained above pH 7-0. The first urine culture after initiation of therapy was taken on the second to fourth day, and then when the gentamicin therapy was concluded. Thereafter the patients were followed up by urine cultivations every month.
The patients were carefully observed for toxic side effects. Before and after gentamicin therapy they were examined by Dr. J. Wersall of the otological clinic, the Karolinska Hospital, with special concern for vestibular function. ' The highest concentration in serum was obtained in the one-hour specimens, and the maximum concentration found was 6-4 ,ug./ml. (case 24). However, the majority of the one-hour values were approximately 2-3 ,ug./ml. (Fig. 2) . Four hours after injection the patients in group III had the highest values of 3-8 and 2-9 ,ug./ml. while the patients in group I with the best kidney function reached a value of only 1-5 ,ug./ml. in spite of a larger dose. The same tendency was apparent in the eight-and 12-hour values, the maximum concentration measured was 3-6 and 2 5 jig./ml., respectively. With the majority of patients the eight-and 12-hour values of gentamicin were very low, approximately 1 ,ug./ml. serum. active gentamicin in the urine was reached within one hour (Fig. 3) . In group I the maximum value measured after one hour was 72 ,ug./ml., and the lowest value was 19 ,ug./ml. Four hours after injection the concentration varied between 24 and 32 pg./ml., after eight hours between 8 and 29 pg./ml., and after 12 hours between 4 and 26 ,ug./ml.
In group II a maximum value of 73 ,ug./ml. was reached after one hour; the lowest concentration was 14 ,ug./ml. After four hours the values varied between 5 and 66 ,g./ml., after eight hours between 5 and 36 ,ug./ml., and after 12 hours between 1 and 36 ,ug./ml.
In of the patients the relapse was caused by the original strain, presumed only by a comparison of the antibiograms of the strains belonging to the same species isolated before gentamicin treatment and after relapse. In one patient (case 5) the original Klebsiella strain was replaced by a mixed flora of E. coli and Streptococcus faecalis; and in another patient (case 11) the Klebsiella strain was replaced by an Alkaligenes faecalis strain.
According to the in vitro test the average serum levels after one hour did not exceed the concentration necessary to inhibit the isolated bacteria at pH 7-4. The gentamicin concentration in the urine, however, stayed above the M.I.C. value in all the patients during the entire period of treatment. The concentration exceeded the corresponding M.B.C. value in 17 of the 19 patients where the M.I.C. and M.B.C. values had been determined. With the two patients (cases 2 and 12) in whom the M.B.C. concentration in the urine was not reached the results of treatment were good nevertheless, since both patients still had negative urine cultures after an observation time of 14 and nine months, respectively.
Case 8, who was treated by haemodialysis, developed a Klebsiella sepsis. Gentamicin treatment was initiated in a dose high in proportion to the kidney function: 2-4 mg./kg. bodyweight per day for the first day, then 1 2 mg./kg. bodyweight per day during the next three days. The general condition of the patient improved dramatically by the first day and the blood cultures were negative.
DISCUSSION
The in vitro investigations showed that gentamicin had a broad spectrum against the majority of Gramnegative rods and Staphylococcus aureus. The average M.I.C. at pH for the 338 cultures investigated (Table I ) was between 0-3 and 2-2 ,tg./ml.; none required more than 40 jtg. gentamicin/ ml. The concentration necessary for bactericidal effects was about two to four times higher than that required for the inhibition of bacterial growth. Against E. coli and Klebsiella, gentamicin showed nearly the same in vitro activity as kanamycin and colistin (Table II) . A comparison of the activity of these three antibiotics against Proteus species and Pseudomonas aeruginosa indicated that gentamicin was an effective agent against both species, whereas kanamycin was effective only against Proteus species and colistin only against Pseudomonas. The results obtained from the in vitro tests of the activity of gentamicin are in agreement with earlier reports (Black et al., 1963; Klein et al., 1964; Rubenis et al., 1963; Weinstein et al., 1963a, b) .
The in vitro activity of gentamicin was greater in an alkaline than in an acid medium (Fig. 1) . The concentration required for a bacteriostatic effect at pH 8 was from eight to 30 times lesser than that required at pH values from 5 to 7. Similar results were obtained by Rubenis et al. (1963) . It may be concluded from these facts that the treatment of urinary tract infections with gentamicin should be carried out with patients having an alkaline urine.
To eliminate the risk of toxic side effects, the dosage ofgentamicin was determined individually for each patient with regard to kidney function (Table  III) . The serum concentration did not exceed 6-3 ,g./ml. in any patient even with the doubled dose of gentamicin (Fig. 2) . After 12 hours only 0 1 to 2 5 ,ug. gentamicin/ml. serum was found. The maximum urine concentrations of gentamicin varied between 21 and 72 ,ug./ml. urine (Fig. 3) . The concentration decreased relatively fast and after 12 hours between 4 and 26 ,ug./ml. was found.
The excretion of active gentamicin in the urine varied between 43% and 98% of the given dose (Fig. 4) . The highest excretion was reached in patients with normal kidney function and the lowest in a patient with renal insufficiency. No definite correlation could be found in this material between the patient's kidney function and the quantity of active gentamicin which was excreted. Bulger et al. (1963) reported 30% to 96% excretion of gentamicin in the urine. The high excretion of gentamicin in the urine also in patients with reduced renal function is of great importance in the treatment of patients with chronic urinary tract infections.
The first urine culture after initiation of the therapy was negative in all patients and 12 of the 24 patients still have negative cultures one to 14 months later (Table III) . The cause of the relapse in 12 of the patients may be that this material consisted ofpatients with chronic pyelonephritis often complicated by, e.g., calculus (Table III) . Before gentamicin therapy was initiated all the patients had been treated with a number of antibiotics and chemotherapeutics without lasting effects. Chronic urinary tract infections often recur after cessation of treatment, and as a rule only about 20% are cured (Kass, 1955; Grieble and Jackson, 1958; Turck, Browder, Lindemeyer, Brown, Anderson, and Petersdorf, 1962) . In the report given more than 50 % of the patients were cured. This may be due to the fact that on the sixth day of gentamicin therapy the patients were put on long-term treatment with either sulphonamides, nitrofurantoin, or acidifying agents (Table III) .
No significant development of resistance to gentamicin of the bacteria which caused a relapse could be established. This observation differs from the experiences reported by Jao and Jackson (1963) who found a tendency towards increased iesistance in vitro of the relapsing strain against gentamicin.
Serious toxic side effects in the form of irreversible labyrinth damage from gentamicin treatment were reported by Jao and Jackson (1963) and Bulger et al. (1963) . Eleven of the patients in our study were carefully observed for ototoxic effects. One of them developed reversible labyrinthine damage after gentamicin treatment; this patient had a chronic pyelonephritis with an endogenous creatinine clearance of 17 ml./min. The dose of gentamicin was low, i.e., 0 4 mg./kg. bodyweight per day. No other toxic manifestations have been observed.
